Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Editas Medicine Inc (NASDAQ: EDIT) closed the day trading at $2.35 down -0.84% from the previous closing price of $2.37. In other words, the price has decreased by -$0.84 from its previous closing price. On the day, 2.1 million shares were traded. EDIT stock price reached its highest trading level at $2.5088 during the session, while it also had its lowest trading level at $2.33.
Ratios:
For a better understanding of EDIT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 5.85 whereas as Long-Term Debt/Eq ratio is at 5.03.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Burkly Linda sold 713 shares for $2.15 per share. The transaction valued at 1,535 led to the insider holds 68,777 shares of the business.
O’Neill Gilmore Neil sold 5,603 shares of EDIT for $12,064 on Dec 03 ’25. The CEO now owns 269,087 shares after completing the transaction at $2.15 per share. On Dec 03 ’25, another insider, Parison Amy, who serves as the SVP, Chief Financial Officer of the company, sold 461 shares for $2.15 each. As a result, the insider received 993 and left with 15,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 229403840 and an Enterprise Value of 83407848. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.95 while its Price-to-Book (P/B) ratio in mrq is 16.29. Its current Enterprise Value per Revenue stands at 1.798 whereas that against EBITDA is -0.744.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.13, which has changed by 0.80916035 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.54, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -18.46%, while the 200-Day Moving Average is calculated to be -0.58%.
Shares Statistics:
Over the past 3-months, EDIT traded about 2.50M shares per day on average, while over the past 10 days, EDIT traded about 1714070 shares per day. A total of 97.62M shares are outstanding, with a floating share count of 97.12M. Insiders hold about 0.51% of the company’s shares, while institutions hold 45.44% stake in the company. Shares short for EDIT as of 1764288000 were 10568381 with a Short Ratio of 4.22, compared to 1761868800 on 8665653. Therefore, it implies a Short% of Shares Outstanding of 10568381 and a Short% of Float of 10.850000399999999.
Earnings Estimates
The performance of Editas Medicine Inc (EDIT) in the stock market is under the watchful eye of 6.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.63 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.06, with 8.0 analysts recommending between -$0.62 and -$1.41.
Revenue Estimates
12 analysts predict $8.45M in revenue for. The current quarter. It ranges from a high estimate of $40.5M to a low estimate of $500k. As of. The current estimate, Editas Medicine Inc’s year-ago sales were $30.6MFor the next quarter, 12 analysts are estimating revenue of $1.38M. There is a high estimate of $3.77M for the next quarter, whereas the lowest estimate is $500k.
A total of 13 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $56.28M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $23.63M. In the same quarter a year ago, actual revenue was $32.31MBased on 13 analysts’ estimates, the company’s revenue will be $16.65M in the next fiscal year. The high estimate is $41M and the low estimate is $2M.
